Industry Reports

Merck known as MSD outside the United States and Canada, announced that Dr. Roger M. Perlmutter, president, Merck Research Laboratories, will present an overview of the company’s oncology program at the 52nd Annual Meeting of the American Society of...

Baxalta Incorporated , Velocity Pharmaceutical Development, LLC and Astellas Pharma Inc announced that Thunderbolt, Inc., a company established by Vitesse Biologics, acquired all rights to the Astellas BAFF/APRIL dual antagonist program through an asset purchase agreement. The BAFF/APRIL dual...

Merck announced that the Board of Directors has declared a quarterly dividend of $0.46 per share of the company’s common stock for the third quarter of 2016. Payment will be made on July 8, 2016 to shareholders of record...

Healthcare and Life Science drive Group organic sales growth (+4.7%) Sigma-Aldrich acquisition fuels sales (+20.5%) and EBITDA pre exceptionals (+27.0%) Integration of Sigma-Aldrich proceeding according to plan Net financial debt lowered by around € 600 million Merck confirms...

Strong fit with Pfizer’s Inflammation and Immunology portfolio Expected to enhance near-term revenue growth for the innovative business Anacor’s flagship asset, crisaborole, has a New Drug Application under review by the U.S. Food and Drug Administration (FDA), is...

Group sales rise by 2 percent – adjusted by +4 percent Adjusted EBITDA declines slightly by 1 percent Adjusted net income increases by 6 percent Sales increase in Branded Products by +3 percent – adjusted +4 percent Very...

Sanofi Files for Hart-Scott-Rodino Notification Regarding Proposed Acquisition of Medivation Sanofi announced that it has filed for premerger notification under the Hart-Scott-Rodino Antitrust Improvements Act of 1976 (HSR) with the U.S. Department of Justice Antitrust Division...